Priftin 150 mg FC tablets.
PDF Leaflet Revision Date: 21 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of latent tuberculosis infection in high-risk patients.
Dosage (summary)
Once-weekly for 12 weeks, max 900 mg based on weight.
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not safe in pregnancy; avoid breastfeeding.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Hormonal contraceptives
- Digoxin
Contraindications
- Hypersensitivity to rifapentine
- Porphyria
- Liver disease
Common side effects
- Hypersensitivity
- Nausea
- Headache
- Fatigue
Counselling Points
- Take with food
- Monitor for hypersensitivity reactions
- Avoid missing doses
Serious warnings
- Hepatotoxicity
- Severe cutaneous adverse reactions
- Clostridium difficile-associated diarrhoea
Important Disclaimer
The Priftin 150 mg FC tablets. professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
